排序方式: 共有3条查询结果,搜索用时 15 毫秒
1
1.
Kallel-Bayoudh Imen Hassen Hanen Ben Khabir Abdelmajid Boujelbene Noureddine Daoud Jamel Frikha Mounir Sallemi-Boudawara Tahia Aifa Sami Reba Ahmed 《Medical oncology (Northwood, London, England)》2010,27(1):55-58
Appearance of non-Hodgkin’s lymphomas (NHL) and renal cell carcinoma (RCC) in same person has been reported in the literature.
There is a higher-than-expected incidence of co-occurrence of these neoplastic disorders. The cause for this association remains
speculative. Two epidemiological studies have shown that the observed-to-expected ratio for occurrence of RCC in NHL patients
were 1.86 to 2.67. We herein describe five patients with both RCC and lymphoid malignancies, and reviewed possible explanations
for the association. In three of the five patients, RCC was diagnosed during lymphoproliferative disease work-up, and remaining
two cases had been diagnosed with chronic lymphocytic leukemia 1 and 5 years prior to RCC. All RCC cases were detected during
staging of the primary tumor, usually by CT scan and/or ultrasound. Our data are in correlation with the literature that there
is an increased association of RCC and NHL more often among male patients, and that the lymphoproliferative disease often
presents with extranodal involvement. The specialists should be alerted for this possibility when evaluating patients at diagnosis
or during follow-up. 相似文献
2.
Imen Kallel-Bayoudh Hanen Ben Hassen Abdelmajid Khabir Noureddine Boujelbene Jamel Daoud Mounir Frikha Tahia Sallemi-Boudawara Sami Aifa Ahmed Rebaï 《Medical oncology (Northwood, London, England)》2011,28(1):55-61
Many biomarkers for breast cancer prognosis have been proposed during the last two decades, among which HER2 and oestrogen receptors are of common use in routine clinical practice. However, in recent years, BCL2 has been recognized as an important prognostic parameter in human breast cancer, although its clinical utility is well established. The aim of this study was to examine the protein expression patterns of BCL2, HER2, oestrogen (ER) and progesterone receptors (PR) and to evaluate their correlation with survival and other prognostic parameters such as tumour size, histological grade and metastasis. We used a retrospective study including 84 Tunisian women with breast cancer. Immunohistochemistry was used to measure protein expression levels of several biomarkers. Association with conventional biopathological factors was analysed by SPSS (version13). The expression rates of BCL2, HER2, ER and PR were, respectively, 69, 62, 58.3 and 51.2%. In univariate analyses, BCL2 was highly correlated with both PR (P < 0.001) and ER (P = 0.006) and also with HER2 expression (P = 0.001). The triple negative profile showed a significant association with SBR (P = 0.016) and BCL2 expression (P = 0.02). In multivariate analyses, a significant association was maintained between BCL2 and both PR and ER (P = 0.02 and P = 0.004, respectively). Survival analysis showed that BCL2 expression was positively correlated with patients survival (P = 0.032). A Bayesian network analysis of all the variables confirmed the high value of BCL2 expression as a predictor of survival. As conclusion, BCL2 expression seems to be a very useful factor that should be in combination with HER2 and ER in breast cancer prognosis. 相似文献
3.
Kallel-Bayoudh I Hassen HB Khabir A Boujelbene N Daoud J Frikha M Sallemi-Boudawara T Aifa S Rebaï A 《Medical oncology (Northwood, London, England)》2011,28(Z1):S55-S61
Many biomarkers for breast cancer prognosis have been proposed during the last two decades, among which HER2 and oestrogen receptors are of common use in routine clinical practice. However, in recent years, BCL2 has been recognized as an important prognostic parameter in human breast cancer, although its clinical utility is well established. The aim of this study was to examine the protein expression patterns of BCL2, HER2, oestrogen (ER) and progesterone receptors (PR) and to evaluate their correlation with survival and other prognostic parameters such as tumour size, histological grade and metastasis. We used a retrospective study including 84 Tunisian women with breast cancer. Immunohistochemistry was used to measure protein expression levels of several biomarkers. Association with conventional biopathological factors was analysed by SPSS (version13). The expression rates of BCL2, HER2, ER and PR were, respectively, 69, 62, 58.3 and 51.2%. In univariate analyses, BCL2 was highly correlated with both PR (P < 0.001) and ER (P = 0.006) and also with HER2 expression (P = 0.001). The triple negative profile showed a significant association with SBR (P = 0.016) and BCL2 expression (P = 0.02). In multivariate analyses, a significant association was maintained between BCL2 and both PR and ER (P = 0.02 and P = 0.004, respectively). Survival analysis showed that BCL2 expression was positively correlated with patients survival (P = 0.032). A Bayesian network analysis of all the variables confirmed the high value of BCL2 expression as a predictor of survival. As conclusion, BCL2 expression seems to be a very useful factor that should be in combination with HER2 and ER in breast cancer prognosis. 相似文献
1